Trials / Completed
CompletedNCT04572152
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human (FIH), Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AK119 | Subjects will receive AK119 by intravenous administration. |
| BIOLOGICAL | AK104 | On the same day subjects will receive AK104 by intravenous administration. |
Timeline
- Start date
- 2020-12-07
- Primary completion
- 2023-05-02
- Completion
- 2023-08-31
- First posted
- 2020-10-01
- Last updated
- 2025-02-28
Locations
5 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04572152. Inclusion in this directory is not an endorsement.